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Abstract
Tubule-interstitial injury (TII) is a critical step in the progression of renal disease. It has been
proposed that changes in proximal tubule (PT) albumin endocytosis plays an important role
in the development of TII. Some reports have shown protective effects of lithium on kidney
injury animal models that was correlated to proteinuria. We tested the hypothesis that lithium
treatment ameliorates the development of TII due to changes in albumin endocytosis. Two
experimental models were used: (1) TII induced by albumin overload in an animal model; (2)
LLC-PK1 cells, a PT cell line. Lithium treatment ameliorates TII induced by albumin overload
measured by (1) proteinuria; (2) collagen deposition; (3) area of tubule-interstitial space,
and (4) macrophage infiltration. Lithium treatment increased mTORC2 activity leading to the
phosphorylation of protein kinase B (PKB) at Ser473 and its activation. This mechanism
enhanced albumin endocytosis in PT cells, which decreased the proteinuria observed in TII
induced by albumin overload. This effect did not involve changes in the expression of mega-
lin, a PT albumin receptor. In addition, activation of this pathway decreased apoptosis in
LLC-PK1 cells, a PT cell line, induced by higher albumin concentration, similar to that found
in pathophysiologic conditions. Our results indicate that the protective role of lithium treat-
ment on TII induced by albumin overload involves an increase in PT albumin endocytosis
due to activation of the mTORC2/PKB pathway. These results open new possibilities in
understanding the effects of lithium on the progression of renal disease.
Introduction
Lithium salts have been used largely to treat mood disorders, including mania and depression
[1,2]. However, this therapy is compromised due to induction of nephrotoxicity after long-
term treatment in both animal models and human patients [1–5]. On the other hand, some
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reports showed that lithium treatment attenuated acute kidney injury (AKI) induced by genta-
micin, cisplatin, lipopolysaccharide (LPS), and ischemia/reperfusion (IR) in animal models
[6–8]. This protective effect of lithium was associated with action on the cortical tubular seg-
ments, indicating that lithium modulates proximal tubule (PT) function and tubule-interstitial
injury (TII).
One possible cause of TII can be correlated to albumin overload in PT followed by an
increase in glomerular permeability to plasma albumin [9–13]. Albumin overload promotes
modifications in the cellular machinery mediating PT albumin reabsorption, which has been
described to induce TII and to contribute to genesis of proteinuria [9–13]. In this context,
some studies have proposed that short-term lithium treatment reduces proteinuria in different
animal models of renal disease [14–16]. However, the role of lithium on PT albumin reabsorp-
tion and its correlation with the development of TII have still to be determined.
Albumin reabsorption in PT cells occurs by receptor-mediated endocytosis; megalin is the
main receptor involved in this process [12,13,17]. Previous studies showed that megalin
expression is decreased when PT cells are exposed to the higher albumin concentration found
in pathophysiologic conditions [18–20]. It was proposed that megalin expression is a sensor
for the development of TII induced by overload of albumin in PT, connecting changes in albu-
min concentration in the lumen of PT cells with intracellular pathways [18,19].
Previous studies have shown that there is a strict correlation between protein kinase B
(PKB) activity and albumin endocytosis in PT cells, which is involved in TII induced by albu-
min overload [18,19,21–23]. Previously, our group showed that a higher albumin concentra-
tion decreases megalin expression and albumin endocytosis, leading to inhibition of PKB
activity and, consequently, induction of cell death [18]. It is well known that PKB activation
depends on the phosphorylation of 2 residues, serine 473 (Ser473) and threonine 308
(Thr308), by mammalian target of rapamycin complex 2 (mTORC2) and phospholipid depen-
dent kinase 1 (PDK1), respectively [24]. It was shown that a higher albumin concentration
induces PKB inhibition through a decrease in mTORC2 activity [19]. Interestingly, it has been
shown that lithium increased PKB activity in different cell types [25–29]. Furthermore, lithium
treatment reduces apoptosis in cortical tubular segments in an AKI model induced by injec-
tion of LPS [6].
Based on these observations, we can postulate that lithium treatment could modulate TII
development due to changes in the machinery mediating albumin endocytosis. To test this
hypothesis, we verified the effect of lithium on an animal model of TII induced by albumin
overload. We observed that lithium treatment partially prevents the development of TII
induced by albumin overload. This effect involves modulation of the mTORC2/PKB pathway
and albumin endocytosis. These results open new possibilities in understanding the effects of
lithium on renal disease.
Materials and methods
Materials and reagents
Bovine serum albumin (BSA), BSA conjugated to fluorescein isothiocyanate (BSA-FITC), lith-
ium carbonate, sodium chloride, potassium chloride, magnesium chloride, calcium chloride,
sodium orthovanadate, sodium pyrophosphate, sodium fluoride, sodium β-glycerophosphate,
sodium azide, sodium carbonate, sodium hydroxide, ammonium persulfate, glycine, D(+)-glu-
cose, Triton X-100, Tween 20, 4-morpholinopropanesulfonic acid (MOPS), EGTA, HEPES,
periodic acid-Schiff reagent, Sirius red, Harry’s hematoxylin, streptavidin-peroxidase, Folin and
Ciocalteu’s phenol reagent, protease inhibitor cocktail (no. I3786), tetramethylethylenediamine,
acrylamide, bromophenol blue, 2-mercaptoethanol, Ponceau S, and phenylmethylsulfonyl
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fluoride (PMSF) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium/potassium
tartrate, copper(II) sulfate, and glycerol were purchased from Reagen (Colombo, PR, Brazil).
Polyvinylidene fluoride (PVDF) membranes, methanol, dimethyl sulfoxide, and wortmannin
were purchased from Merck Millipore (Barueri, SP, Brazil). ECL Prime, sodium dodecyl sulfate
(SDS), and Tris were purchased from GE Healthcare (Pittsburgh, PA, USA). LDH Liquiform
kit (no. 86-2/30), BUN kit (no. 27–500), and Sensiprot kit (no. 36) were purchased from Labtest
(Lagoa Santa, MG, Brazil). Creatinine kit (no. 335) was purchased from Gold Analisa (Belo
Horizonte, MG, Brazil). Sodium enzymatic kit (no. 573351) was purchased from In Vitro Diag-
nóstica (Itabira, MG, Brazil). MK-2206 was purchased from Selleckchem (Houston, TX, USA).
Annexin V:FITC apoptosis detection kit I was purchased from BD Biosciences (São Paulo, SP,
Brazil). Polyclonal phospho-mTOR (Ser-2481), monoclonal mTOR (clone 7C10), polyclonal
phospho-PKB (Ser-473), polyclonal PKB, polyclonal iNOS, polyclonal β-actin and HRP-conju-
gated anti-rabbit IgG antibodies were purchased from Cell Signaling Technology (Danvers,
MA, USA). Polyclonal albumin, monoclonal GSK3β (clone 3D10), polyclonal phosphorylated
GSK3β (Ser9) and polyclonal Lrp2/megalin antibodies were purchased from Abcam (Cam-
bridge, MA, USA). Monoclonal F4/80 antibody (clone A3-1) was purchased from AbD Serotec
(Raleigh, NC, USA). Monoclonal arginase-1 antibody (clone 19) was purchased from BD Trans-
duction (Mississauga, ON, Canada). Biotinylated anti-rabbit or anti-mouse IgG was purchased
from Agilent Technologies (Santa Clara, CA, USA). Dulbecco’s modified Eagle’s medium
(DMEM), PBS, 40,6-diamidino-2-phenylindole (DAPI), fetal bovine serum (FBS), 3,30-diamino-
benzidine (DAB), and UltraPure N,N0-methylenebisacrylamide were purchased from Thermo
Fisher Scientific (Waltham, MA, USA). Vectashield antifade mounting medium was purchased
from Vector Laboratories (Burlingame, CA, USA). LLC-PK1 cells were obtained from the
American Type Culture Collection (Rockville, MD, USA). All other reagents were of the highest
purity available.
Animals and experimental protocol
Male BALB/C mice (8–11 weeks old), weighing 20–25 g, were obtained from the Institute of
Science and Technology in Biomodels (ICTB) of the Oswaldo Cruz Foundation (FIOCRUZ),
Rio de Janeiro, Brazil. The animals were accommodated in an air-conditioned environment
(22–24˚C) in a regular 12-h light/dark cycle with water and standard chow ad libitum. All pro-
cedures involving the handling of animals were conducted in accordance with the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Ethics Committee of the Federal University of Rio de Janeiro
(protocol number 043/18). During the study, the presence or absence of adverse clinical signs
associated with the BALB/C strain such as male aggression, corneal opacity, conjunctivitis, ble-
pharitis, or periorbital abscesses was checked. In addition, other possible abnormalities such as
skin lesions, occurrence of tumors, hydration status, body condition, and abnormalities in the
teeth, genitals, and abdomen were analyzed. Furthermore, general behavior aspects such as
degree of mobility inside the cage, interaction with cage mates, eating, drinking, absence of
feces or diarrhea, and the ability of the animals to build a nest were also monitored.
The animal model of TII induced by albumin overload was developed as described previ-
ously [22,30,31]. Briefly, mice were randomly divided into 4 experimental groups: (1) control
group (CONT); (2) BSA-treated group (BSA) subjected to intraperitoneal (i.p.) injection of
BSA 10 g/kg/day for 7 consecutive days; (3) simultaneous BSA and lithium-treated group
(BSA+LIT), subjected to simultaneous i.p. injection of BSA and lithium administration 300
mg/kg/day via gavage; (4) lithium-treated group (LIT), subjected to lithium administration
alone. The CONT and LIT groups received i.p. injections with saline used as vehicle for BSA.
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From day 5 to day 7 of treatment, the animals were housed in metabolic cages to allow bio-
chemical analysis of urine and other clinical parameters. In order to minimize suffering, the
animals were euthanized at the end of day 7 with a combination of the following anesthetics:
ketamine (240 mg/kg body weight) and xylazine (15 mg/kg body weight). The kidneys and
blood were then collected for different analyses. When indicated, the kidneys were prepared
for: (1) histologic and immunohistochemistry studies; (2) protein phosphorylation or protein
expression in the homogenate fraction of the renal cortex; or (3) in vivo PT albumin
reabsorption.
Analysis of renal function
Analysis of renal function was performed as described previously [22,30–32]. Briefly, the 24-h
urine was collected to determine urinary flow (μL/min). Then, the urine samples were clarified
by centrifugation at 600 × g for 10 min to remove urine sediments, and the supernatant was
used to determine the protein, creatinine, and sodium levels. Plasma samples were obtained
after centrifugation of the blood samples collected by cardiac puncture (600 × g for 2 min).
Plasma samples were used to determine creatinine, sodium, and blood urea nitrogen (BUN)
levels. All these parameters were determined using commercial kits available from Gold Ana-
lisa and Labtest (Brazil). The creatinine levels were determined by the alkaline picrate method.
25 μL of non-diluted plasma or diluted urine (50×) was added to 250 μL of a reaction medium
containing picric acid. The levels of urinary protein were determined by the pyragallol red
method. BUN levels were measured using the urease method. Sodium levels were determined
by precipitation with uranyl-magnesium acetate. The results were used to calculate the creati-
nine clearance (CCr), urinary protein/urinary creatinine ratio (UPCr), and fractional excre-
tion of sodium (FENa+).
In vivo albumin reabsorption assay
The in vivo albumin reabsorption assay was carried out as described previously [33]. Briefly,
the mice were anesthetized and infused intravenously with a single dose of 5 μg/g BSA-FITC
used as a tracer. Other mice were infused with the vehicle (used as a blank). After 15 min of
infusion, the mice were perfused with heparinized saline to extract serum contaminants and
the non-accumulated BSA-FITC, and the kidneys were removed. Then, the renal cortex was
isolated and homogenized in ice-cold Ringer solution (20 mM HEPES-Tris [pH 7.4], 140 mM
NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM D(+)-glucose) containing 1 mM
PMSF and protease inhibitor cocktail 1×. The homogenate was clarified twice by centrifuga-
tion at 15,000 × g at 4˚C for 10 min. The supernatant obtained was used to determine the fluo-
rescence intensity accumulated in the kidneys. Fluorescence intensity (excitation = 480 nm,
emission = 520 nm) was quantified with SpectraMax M2 (Molecular Devices, Sunnyvale, CA).
The BSA-FITC-specific uptake was calculated as the difference between the fluorescence units
obtained in the homogenate of BSA-FITC-injected mice and those obtained in the homoge-
nate of blank mice. These BSA-associated fluorescence values were normalized to the total pro-
tein concentration in the sample using the Folin phenol method as described previously [34].
Data were expressed as arbitrary units.
Histologic and immunohistochemistry studies
The histologic and immunohistochemistry studies were performed as described previously
[22,30–33]. Briefly, the euthanized mice were perfused with saline and 4% paraformaldehyde
using a peristaltic pump at a flow rate of 10 mL/min. The kidneys were removed and fixed in
Gendre solution for 24 h, in 10% buffered formalin for 48 h, and then embedded in paraffin.
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The kidneys were sectioned in different sizes. First, 5-μm-thick sections were stained with peri-
odic acid-Schiff reagent for analysis of the area of cortical interstitial space. These sections
were also used to determine F4/80-positive cells and megalin expression through immunohis-
tochemistry assays. Then 8-μm-thick sections were stained with Picrosirius red for analysis of
cortical collagen deposition. In the immunohistochemistry studies, the detection of F4/80-pos-
itive cells and megalin was performed using specific antibodies according to the manufactur-
er’s instructions. Biotinylated anti-rabbit or anti-mouse IgG was followed by streptavidin-
peroxidase, both for 1 h at room temperature. Positive reactions (brown staining) were
revealed with DAB, and the sections were counterstained with Harry’s hematoxylin.
All images from the renal cortex were obtained using a Nikon 80i eclipse microscope
(Nikon, Japan). All quantification analysis was performed using Image-Pro Plus image analysis
software (Media Cybernetics, Inc., USA) in at least 30 randomly captured photomicrographs.
To specifically assess the cortical tubular interstitial area, photomicrographs containing large
blood vessels and glomeruli were excluded. Analysis of the area of interstitial space was per-
formed by directly measuring the area among the tubules. Collagen deposition analysis was
performed by measuring the density of red fibers. Data were expressed as a percentage of the
interstitial area with positive staining. The density of F4/80-positive cells and megalin levels
was measured by the area with positive staining. Data were expressed as a percentage of the
total tissue area.
Cell culture
Cell culture procedures were carried out as described previously [18,19,21–23,33]. Briefly,
LLC-PK1 cells were maintained in low-glucose DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin (37˚C and 5% CO2) until 95% confluence was reached (typically 2
days after seeding). Then, the cells were washed twice with PBS and incubated with FBS-
depleted medium in the presence or absence of albumin and/or lithium under different experi-
mental conditions described in the Results section. When indicated, the cells were pre-incu-
bated with specific inhibitors. Serum starvation was done to keep several signaling proteins
triggered by growth factors under a basal state of activation. After treatment, the cells were
used in different experimental assays such as albumin endocytosis, protein phosphorylation
through immunoblotting, and apoptotic cell rate through flow cytometry [18,19,21–23,33].
Cell viability during different experiments was determined by LDH activity in the cell superna-
tant via the NADH oxidation method using a commercial kit.
In vitro albumin endocytosis
In vitro albumin endocytosis was measured with a BSA-FITC uptake assay as described previ-
ously [21,23,33]. Briefly, the treated cells were washed 3 times with pre-warmed Ringer solu-
tion (12.4 mM HEPES-Tris [pH 7.4], 140 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1 mM
MgCl2, 5 mM glucose), and then incubated with Ringer solution containing 30 μg/mL BSA-
FITC at 37˚C for 30 min. After the reaction, the unbound BSA-FITC was removed by washing
11 times with ice-cold Ringer solution. Parallel experiments were performed on cells held at
4˚C to abolish endocytosis and verify possible non-specific bound BSA-FITC. BSA uptake was
assessed by cell-associated fluorescence using albumin-FITC or the fluorescence microscopy
method.
In the cell-associated fluorescence method, the cells were lysed using detergent solution
(0.1% Triton X-100 in 20 mM MOPS) and the cell-associated fluorescence was measured
using a microplate spectrofluorimeter (SpectraMax M2, Molecular Devices, Sunnyvale, CA,
USA). BSA-specific uptake was calculated as the difference between the BSA-FITC uptake in
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the absence and in the presence of 20 mg/mL unlabeled BSA. The blank in the experiment was
defined as the fluorescence measured in the absence of BSA-FITC; its value was less than 10%
of the total fluorescence. The BSA-specific uptake values were further normalized by the total
protein concentration in the samples using the Folin phenol method [34].
For fluorescence microscopy, the cells were fixed with 4% paraformaldehyde at 25˚C for 15
min and permeabilized with 0.1% Triton X-100 for 1–2 min. To stain the cell nucleus, the cells
were incubated with DAPI. The cells were then mounted in Vectashield medium. To quantify
albumin endocytosis, images of fluorescent-labeled markers were acquired with a Leica TCS
SP8 confocal microscope using a ×63 oil immersion objective lens, and the average intensity
per cell was calculated using Image-Pro Plus software v7.0.1.658 (Media Cybernetics, Rock-
ville, MD, USA) from multiple images after subtracting the background.
Preparation of the renal cortex homogenate fraction
The renal cortex homogenate fraction was obtained as described previously [30–33]. Briefly,
the euthanized mice were perfused with heparinized saline using a peristaltic pump with a
flow rate of 10 mL/min, and the kidneys were then removed. The renal cortex was isolated
using a microtome and homogenized in a cold solution containing 250 mM sucrose, 10 mM
HEPES-Tris (pH 7.6), 2 mM EDTA, and 1 mM PMSF. The homogenate was clarified twice by
centrifugation at 15,000 × g at 4˚C for 10 min. The supernatant obtained was stored at −80˚C
until use.
Immunoblotting
Immunoblotting was performed as previously described [18,19,21–23,33]. Briefly, cells were
washed 5 times with ice-cold PBS and incubated in ice-cold lysis buffer (20 mM HEPES [pH
7.4], 2 mM EGTA, 1% Triton X-100, 50 mM sodium fluoride, 5 mM sodium orthovanadate, 5
mM sodium pyrophosphate, 10 mM sodium β-glycerophosphate, 1 mM PMSF and 2× prote-
ase inhibitor cocktail) for 40 min. The cells were then clarified by centrifugation (4˚C for 13
min at 15,000 × g). The supernatant was collected and the total protein concentration was
quantified by the Folin phenol method [34]. The renal cortex homogenate was obtained and
the total protein concentration was determined as described above. Proteins obtained from
both the cell lysate and renal cortex homogenate fraction (range, 30–60 μg) were resolved on
9% SDS-PAGE and transferred to PVDF membranes (Millipore Corporation, Billerica, MA,
USA), according to the manufacturer’s instructions. When indicated, the presence of iNOS,
arginase-1, phospho-PKB (Ser473), PKB, phospho-mTOR (Ser2481), mTOR, urinary albumin
and β-actin was determined using specific antibodies according to the manufacturer’s instruc-
tion. After labeling with primary and HRP-conjugated secondary antibodies, the detection of
specific bands was performed using ECL Prime as the substrate for HRP. The images were
acquired by chemiluminescence using ImageQuant LAS4000 (GE Healthcare Life Sciences).
All images were processed by adjusting the brightness and contrast using NIH ImageJ software
(version 1.6.0). This image processing method was applied to every pixel in the original image
without changing the information illustrated. The optical density (OD) of the bands was also
quantified using ImageJ. In each experiment, the OD related to phospho bands (PKB and
mTOR) were normalized to the OD of the total protein bands obtained after stripping and re-
probing the same membrane with the corresponding antibodies. The same procedure was per-
formed for the assessment of iNOS and arginase-1 expression. The OD of their respective
bands was normalized by the OD of bands related to β-actin.
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Analysis of cell apoptosis
Cell apoptosis was determined by the annexin V-FITC labeling as described previously [18].
Briefly, monolayer cells were released by brief incubation with a trypsin-EDTA solution. Then,
105 cells were resuspended in 1× binding buffer (BD PharMingen) and incubated with annexin
V-FITC for 15 min at room temperature in the dark, followed by staining with propidium
iodide. Cells were analyzed within 1 h in a FACSCalibur flow cytometer, and Cellquest soft-
ware (Becton Dickinson) was used to analyze the data. Data are presented as the frequency of
early apoptotic cells (annexin-V-FITC-positive cells).
Statistical analysis
The results are expressed as means ± standard error (SE). GraphPad Prism 7 (version 7,
GraphPad Software, San Diego, CA, www.graphpad.com) was used for the statistical analysis.
Differences between groups were compared by one-way analysis of variance, followed by the
Newman-Keuls post test. Significance was determined as P< 0.05.
Results
Renal parameters
In the present work, a model of TII induced by albumin overload was used [22,30,31]. The
experimental animals were divided into 4 groups as described in the earlier. Table 1 shows the
values for body weight, water and food intake, urinary flow, serum creatinine (SCr), urinary
creatinine, CCr, BUN, and FENa+. We did not observe any changes in body weight, food
intake, SCr, CCr, and BUN levels in any experimental group. However, both the BSA+LIT and
LIT groups presented higher water intake and urinary flow and decreased urinary creatinine
levels compared with the CONT group. The BSA, BSA+LIT, and LIT groups showed an
increased level of FENa+ compared with the CONT group, indicating modifications in tubular
reabsorption.
Lithium treatment reduces proteinuria and is correlated to a reduction in
albumin reabsorption in PT cells
Because proteinuria is a marker of renal injury, we decided to investigate it in different experi-
mental groups. The level of proteinuria was increased in the BSA group compared with the
CONT group (Fig 1A). On the other hand, this effect was completely reversed in the BSA+LIT
Table 1. Renal function parameters.
CONT BSA BSA+LIT LIT
Body weight (g) 22.80 ± 0.49 21.20 ± 1.20 21.33 ± 0.88 21.00 ± 0.58
Water intake (mL) 4.80 ± 0.49 4.00 ± 0.32 10.67 ± 3.18� 9.00 ± 1.00�
Food intake (g) 3.63 ± 0.44 2.88 ± 0.23 3.71 ± 0.38 3.93 ± 0.19
Urinary flow (μL/min) 0.70 ± 0.09 0.49 ± 0.06 3.30 ± 1.39� 2.67 ± 0.45�
Serum creatinine (mg/dL) 0.102 ± 0.009 0.102 ± 0.019 0.076 ± 0.001 0.119 ± 0.013
Urinary creatinine (mg/dL) 75.70 ± 15.0 68.85 ± 5.74 34.04 ± 9.80� 17.13 ± 3.11�
Creatinine clearance (mL/min) 0.47 ± 0.06 0.45 ± 0.07 0.55 ± 0.07 0.43 ± 0.08
BUN (mg/dL) 66.83 ± 6.45 65.08 ± 4.66 58.91 ± 7.90 64.16 ± 6.76
FENa+ 0.138 ± 0.0295 0.233 ± 0.0229� 0.352 ± 0.0498� 0.547 ± 0.103�
The results are expressed as means ± SE. Statistically significant in relation to CONT (�P < 0.05).
https://doi.org/10.1371/journal.pone.0215871.t001
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group. Furthermore, proteinuria did not change in the LIT group. To rule out the possible
influence of urinary flow in this parameter, the ratio of urinary protein and urinary creatinine
(UPCr) was measured (Fig 1B). A significant increase in UPCr was observed in the BSA
group, which was partially reversed in the BSA+LIT group. Interestingly, the LIT group also
showed an increased UPCr compared with the CONT group. However, this increase was
lower in magnitude than the increase observed in the BSA group. Similarly, the same profile
was observed when urinary albumin was assessed by immunoblotting (Fig 1C).
To test if these changes in proteinuria promoted by lithium treatment correlate with
changes in tubular protein reabsorption, in vivo PT albumin reabsorption was assessed using
albumin-FITC as a tracer (Fig 1D). A decrease in albumin reabsorption was observed in the
BSA group, which partially reversed by simultaneous treatment with lithium (BSA+LIT
group). The LIT group also showed a decrease in albumin reabsorption compared with the
CONT group but of lesser magnitude than observed in the BSA group. These results agree
with the results for the UPCr, indicating a strict correlation between albumin reabsorption
and proteinuria in PT cells.
Most of the albumin endocytosis in PT cells occurs through megalin-mediated endocytosis
[12,13,17]. In Fig 2, we determined the expression of megalin in the renal cortex. All treated
groups (BSA, BSA+LIT, and LIT) presented lower levels of megalin expression than the
CONT group (Fig 2A and 2B). These results indicate that the changes in albumin reabsorption
Fig 1. Lithium treatment reduces proteinuria induced by albumin overload due to the increase in albumin
reabsorption. Male BALB/C mice were separated into different experimental groups as described in the Materials and
methods section. CONT, control group; BSA, group that received intraperitoneal injections 10 g/kg/day BSA for 7
days; BSA+LIT, group that simultaneously received BSA injection and 300 mg/kg/day lithium carbonate via gavage;
LIT, lithium-treated group. A) Proteinuria (n = 7). B) Ratio of urinary protein and urinary creatinine (UPCr; n = 7).
C) Urinary albumin content was assessed by immunoblotting. Urinary volume was adjusted for 10 μg of urinary
creatinine. D) In vivo albumin reabsorption (n = 4). Mice received a single intravenous dose of 5 μg/g BSA-FITC used
as a tracer. After 15 min, the animals were perfused with saline and the BSA-specific fluorescence intensity in the renal
cortex was determined. The results are expressed as means ± SE. �P< 0.05 versus CONT group; #P< 0.05 versus BSA
group.
https://doi.org/10.1371/journal.pone.0215871.g001
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observed in lithium-treated animals are not due to changes in megalin expression. But how
lithium modulates albumin reabsorption in the TII animal model is still an open matter. One
possibility could be an increase in the endocytosis rate rather than endocytosis receptor
expression.
Lithium modulates albumin endocytosis: Involvement of the PI3K/PKB
pathway
In this context, it has been proposed that the PI3K/PKB pathway has a central role in the mod-
ulation of albumin endocytosis and, consequently, in the development of this renal injury
[18,19,21–23]. We decided to study the modulatory effect of lithium on PT albumin endocyto-
sis and the possible involvement of the PI3K/PKB pathway. To address this question,
LLC-PK1 cells, a model of PT cells, were used. Initially, the cells were incubated with increas-
ing concentrations of lithium (from 0.1 to 20 mM), and albumin endocytosis was measured
after 12 h. Albumin endocytosis was increased with lithium; the maximal effect was obtained
at 20 mM (Fig 3A). The time-course experiments showed that this effect was only observed
after 6 h of incubation and maintained for up to 12 h (Fig 3B). Figs 3C and 4 show the modula-
tory effect of albumin on PT albumin endocytosis by lithium. Incubation of the cells with 20
mg/mL albumin for 12 h inhibited albumin endocytosis. Interestingly, this effect was
completely reversed when cells were incubated simultaneously with lithium. This result was
similar to that obtained in the TII animal model (Fig 1D).
To investigate the possible role of the PI3K/PKB pathway on the stimulatory effect of lith-
ium on albumin endocytosis, LLC-PK1 cells were pre-incubated with 10−7 M wortmannin,
PI3K inhibitor, and 10−6 M MK-2206, a specific PKB inhibitor. Both inhibitors completely
blocked the stimulatory effect of lithium on albumin endocytosis, indicating the role of the
PI3K/PKB pathway (Fig 5A). In agreement with this result, it was shown that lithium increased
PKB activity measured by phosphorylation of the Ser473 residue (Fig 5B). Because the phos-
phorylation of Ser473 is mediated by mTORC2, we decided to investigate its possible modula-
tion by lithium treatment [24]. Interestingly, lithium increased mTORC2 activity, measured
by phosphorylation of Ser2481, similar to that observed with the phosphorylation of Ser473 at
PKB (Fig 5B) [19].
Previously, it was shown that a reduction in PKB activity in the renal cortex is associated
with a decrease in albumin endocytosis induced by higher albumin concentration [22]. Fig 5C
Fig 2. Lithium treatment did not change the inhibition of megalin expression during albumin overload. Mice were
treated as described in Fig 1 (n = 4 per group). A) Representative megalin staining in the cortical area (bars represent
100 μm). B) Quantitative analyses. The results are expressed as means ± SE. �P< 0.05 versus CONT group.
https://doi.org/10.1371/journal.pone.0215871.g002
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shows that 20 mM lithium completely reversed the inhibitory effect of 20 mg/mL albumin on
the phosphorylation of PKB at Ser473, mTORC2 at Ser2481 and GSK3β at Ser9 in LLC-PK1
cells. Moreover, the phosphorylation of all residues was assessed in the renal cortex of TII
induced by albumin overload (Fig 5D). A significant decrease in the phosphorylation of PKB,
mTORC2 and GSK3β was observed in the BSA group compared with the CONT group. On
the other hand, the simultaneous treatment of the animals with lithium (BSA+LIT group)
reversed the inhibitory effect on the phosphorylation of all these kinases observed in the BSA
group.
Usually, modulation of PKB activity is associated with cell death by apoptosis [18,24]. Thus,
the possible effect of lithium in apoptosis induced by high albumin concentration in LLC-PK1
cells was tested. Cell apoptosis was determined using annexin V-FITC and flow cytometry.
The incubation of LLC-PK1 cells with 20.0 mg/mL albumin overnight increased apoptotic
cells, and this effect was completely reversed when the cells were co-incubated with 20 mM
lithium (Fig 6A and 6B). Lithium treatment alone did not change the basal rate of cell
apoptosis.
So far, our results indicate that the modulatory effect of lithium on the inhibition of PT
albumin endocytosis induced by albumin overload involves the activation of PKB, which is
Fig 3. Lithium blockade of the inhibitory effect of high albumin concentration on albumin endocytosis in PT cells
measured by cell-associated fluorescence. LLC-PK1 cells were grown in 24-well plates until 95% confluence was
reached. Then, the cells were incubated with albumin and/or lithium under different experimental conditions.
Albumin endocytosis measured by cell-associated fluorescence using albumin-FITC. A) Dose-response effect of
lithium on albumin endocytosis (n = 9). The lithium concentrations used were 0.1, 1, 5,10, and 20 mM. B) Time-
course effect of lithium on albumin endocytosis (n = 4). Times of incubation were 0, 2, 4, 6, and 12 h. C) Lithium
treatment reversed the inhibitory effect of high albumin concentration on albumin endocytosis (n = 7). The cells were
pre-incubated with 20 mg/mL albumin in the absence or presence of increasing lithium concentrations (5, 10, and 20
mM). The results are expressed as means ± SE. A) �P< 0.05 versus control (in the absence of lithium), #P< 0.05
versus 1 mM lithium; &P< 0.05 versus 10 mM lithium. B) �P< 0.05 versus control (in the absence of lithium). C)
�P< 0.05 versus control (in the absence of albumin), #P< 0.05 versus albumin.
https://doi.org/10.1371/journal.pone.0215871.g003
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mediated by mTORC2 activation. Some evidence shows that changes in PT albumin reabsorp-
tion could be a trigger for TII [10,11,22,30,31,35]. Thus, TII was assessed in the next
experiments.
Tubule-interstitial injury induced by proximal tubule albumin overload is
attenuated by lithium treatment
Initially, Bowman´s capsule space was measured (Fig 7A and 7B). This parameter did not
change in any experimental conditions, in agreement with the plasma levels of creatinine,
BUN and CCr (Table 1). On the other hand, tubule-interstitial space increased in the BSA
group and was completely abolished with concomitant lithium treatment (BSA + LIT group;
Fig 7C and 7D). Interestingly, lithium treatment (LIT group) alone also increased the area of
tubule-interstitial space, similar to the BSA group.
Fig 4. Lithium blockade of the inhibitory effect of high albumin concentration on albumin endocytosis in PT cells
measured by confocal fluorescence microscopy. The cells were pre-incubated with 20 mg/mL albumin and/or 20
mM lithium. A) Representative image. Green (BSA-FITC) indicates endocytic albumin, and blue (DAPI) indicates the
cell nucleus. Scale bar represents 20 μm. DIC, differential interference contrast. B) Quantitative analysis (n = 4). The
results are expressed as means ± SE. The control was taken as 100%. �P< 0.05 versus control (in the absence of
lithium), #P< 0.05 versus albumin.
https://doi.org/10.1371/journal.pone.0215871.g004
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Fig 5. Lithium treatment increases albumin endocytosis due to activation of the mTORC2/PKB/GSK3β pathway.
LLC-PK1 cells were grown in 24-well plates until 95% confluence was reached. Then, the cells were incubated with
different compounds as indicated. A) The stimulatory effect of lithium on albumin endocytosis depends on the PI3K/
PKB pathway (n = 6). The cells were pre-incubated with 10−7 M wortmannin (Wort, PI3K inhibitor) or 10−6 M MK-
2206 (PKB inhibitor) for 30 min before the addition of 20 mM lithium. B) Dose-response of lithium on PKB (Ser473)
and mTORC2 (Ser2481) phosphorylation (n = 3). C) Lithium treatment modulates the inhibitory effect of higher
albumin concentration on PKB (Ser473), GSK3β (Ser9) or mTORC2 (Ser2481) phosphorylation in LLC-PK1 cells
(n = 4). D) Lithium treatment modulates the inhibitory effect of higher albumin concentration on PKB (Ser473),
GSK3β (Ser9) or mTORC2 (Ser2481) phosphorylation in the TII animal model (n = 6). Representative
immunoblotting images are shown. Densitometric quantification was obtained as a ratio of phosphorylated and total
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Collagen deposition was increased in the BSA group and was partially reversed by concomi-
tant lithium treatment (BSA+LIT group; Fig 7E and 7F). Lithium treatment (LIT group) alone
also increased collagen deposition to a level similar to that observed in the BSA+LIT group. So
far, these data suggest that lithium treatment induces a dual effect: (1) tubular damage in
healthy mice; and (2) amelioration of TII induced by albumin overload in PT cells. These
opposite effects could be associated with differential changes in immune cell infiltration, such
as in macrophages.
Fig 8A and 8B shows the extent of macrophage infiltration by measuring the presence of F4/
80-positive cells in the renal cortex. Interestingly, an increase in macrophage infiltration was
observed in all treated groups (BSA, BSA+LIT, and LIT) compared with the CONT group. This
lack of influence of lithium on macrophage infiltration triggered by albumin overload seems to
be contrary to the protective effect of lithium on TII induced by albumin overload, suggesting
another possible effect of lithium, such as modulation of the macrophage phenotype.
To test this hypothesis, iNOS and arginase-1 expression (markers of M1 or M2 subtype
macrophages, respectively) were determined in the renal cortex. We observed that iNOS
expression was only increased in the LIT group (Fig 8C). On the other hand, arginase-1
expression was increased in the BSA group, and this effect was reversed by simultaneous lith-
ium treatment (BSA+LIT group; Fig 8D). The level of arginase-1 expression was not changed
in the LIT and BSA+LIT groups compared with CONT group despite a tendency to be higher.
These results indicate that changes in the balance of M1/M2 phenotype macrophages are asso-
ciated with the effect of lithium on TII induced by albumin overload.
Discussion
Despite the widespread use of lithium for the treatment of mood disorders, the renal effects
are still controversial [2–8]. Some studies indicate that lithium treatment ameliorates AKI
protein. Relative expression is represented as a percentage of control. The results are expressed as means ± SE. A)
�P< 0.05 versus control (in the absence of lithium), #P< 0.05 versus 20 mM lithium. B) �P< 0.05 versus control (in
the absence of lithium). C,D) �P< 0.05 versus control (in the absence of albumin and lithium) or CONT group,
#P< 0.05 versus albumin or the BSA group.
https://doi.org/10.1371/journal.pone.0215871.g005
Fig 6. Lithium treatment protects PT cells against apoptosis induced by high albumin concentrations. LLC-PK1
cells were grown in 24-well plates until reach 95% confluence was reached. Then, the cells were incubated with 20 mg/
mL albumin and/or 20 mM lithium. A) Representative dot plot of the experiments (n = 8). B) Quantitative analysis
showing the frequency of annexin-V-positive cells. �P< 0.05 versus control (in the absence of albumin), #P< 0.05
versus 20 mM albumin.
https://doi.org/10.1371/journal.pone.0215871.g006
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induced by LPS or IR, and this effect is correlated to injuries in cortical nephron segments [6–
8]. We studied the effect of lithium treatment on TII induced by albumin overload. It was
observed that development of TII was attenuated by lithium treatment. We are proposing that
this effect involves modulation of PT albumin endocytosis and activation of the mTORC2/
PKB pathway.
One important concern could be correlated to the dose of lithium used. Some studies have
used a lower dose of lithium chloride (30–80 mg/kg), by intraperitoneal injection, as an
Fig 7. Lithium treatment ameliorates tubule-interstitial injury induced by albumin overload. Mice were treated as
described in Fig 1. A) Representative images of Bowman´s capsule space. B) Quantitative analysis related to A. C)
Representative images of tubule-interstitial space. D) Quantitative analysis related to C (n = 5). E) Representative
Picrosirius staining (red color) in the cortical area. F) Quantitative analysis related to C (n = 8). Scale bars represent
100 μm. The results are expressed as means ± SE. �P< 0.05 versus the CONT group, #P< 0.05 versus the BSA group.
https://doi.org/10.1371/journal.pone.0215871.g007
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inhibitor of GSK-3β to treat renal diseases in LPS-induced or gentamicin-induced AKI model
mouse models [6–8]. In the present study, male BALB/C mice were treated with 300 mg/kg/
day lithium carbonate by gavage. This dose was chosen because it mimics the clinical dose
used to treat mood disorders [36].
For several decades, albuminuria has been used as a marker of progression of renal disease.
More recently, it has been proposed that albumin overload in PT promotes TII, and, conse-
quently, induces progression of renal disease to end-stage renal disease [9–13]. Some authors,
including our group, showed a correlation with albumin overload in PT cells, impairment in
PT albumin reabsorption, and the development of an inflammatory phenotype [20,22,30,31,
35]. In this context, changes in albumin endocytosis in PT cells is a crucial process to deter-
mine both albumin reabsorption and the development of TII.
It has been shown that cubilin assembles with megalin and amnionless, forming a receptor
involved in PT albumin reabsorption [13,37]. However, some authors have proposed that this
complex does not work in the same way for all protein reabsorption in PT cells [38]. It was
observed that cubilin knockout mice do not have significant proteinuria even though they
present mild albuminuria. On the other hand, specific PT cells in megalin knockout mice have
Fig 8. Lithium treatment induces change in M1/M2 phenotype macrophages. Mice were treated as described in Fig 1.
A) Representative areas of macrophage infiltration by F4/80 staining in the cortical area. Arrows denote positive brown
staining. Scale bars represent 100 μm. B) Quantitative analysis related to E (n = 4). C) iNOS expression (n = 8). D)
Arginase-1 expression (n = 8). Both iNOS and arginase-1 bands were detected using specific antibodies. The OD related to
iNOS or arginase-1 bands was normalized to the OD related to the β-actin band. The results are expressed as means ± SE.
�P< 0.05 versus the CONT group.
https://doi.org/10.1371/journal.pone.0215871.g008
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high proteinuria and albuminuria [38]. The aim of the present work was to correlate megalin
expression, PT albumin reabsorption and albuminuria. However, the role of cubilin in the
albuminuria observed under the different experimental conditions cannot be ruled out.
It was shown that lithium treatment reduced albuminuria and proteinuria in animal models
of renal disease, such as lupus and adriamycin-induced kidney injury [14–16]. In agreement,
we also observed that lithium treatment ameliorated the inhibitory effect of high albumin con-
centrations on PT albumin endocytosis in both in vivo and in vitro models, which did not
involve modulation of the albumin receptor megalin. One possibility to explain this effect
could be an increase in the rate of albumin endocytosis induced by post-translation modifica-
tions due to activation of regulatory signaling pathways.
Several studies have pointed out the correlation between PKB activity and albumin endocy-
tosis [18,19,21–23]. It has been well accepted that the PI3K/PKB pathway is a central pathway
to modulate PT albumin endocytosis. Its activation leads to an increase in albumin endocyto-
sis, whereas its inhibition promotes the inhibition of albumin endocytosis [21,23]. On the
other hand, PKB activity could also be modulated by changes in albumin concentration, lead-
ing to modifications in cell survival [18]. A higher albumin concentration decreases megalin
expression, PKB activity, and induces apoptosis promoting cell death. This mechanism was
proposed to be involved in the genesis of TII induced by albumin overload [22]. Here, we
observed that lithium treatment prevented the inhibition of PKB activity by albumin overload
without changes in megalin expression. Indeed, we observed that lithium treatment per se
increased PKB phosphorylation at Ser473. These results indicate that the effect of lithium treat-
ment on albumin endocytosis is due to the increase in PKB activity. In agreement with this
proposal, it was observed that the effect of lithium on albumin endocytosis in LLC-PK1 cells is
abolished by inhibitors of PKB and PI3K.
Modulation of PKB activity by lithium has been observed in different cell types [25–29].
PKB activation induced by lithium is associated with inhibition of apoptosis, and it is proposed
to be involved in the neuroprotective effects of lithium. However, the mechanism involved in
the activation of PKB is still an open matter. Mora et al. [27] proposed that lithium increases
PKB activity due to the inhibition of protein phosphatase-2A induced by ceramide in cerebel-
lar granule cells. In the present work, we observed that lithium increased mTORC2 activity in
LLC-PK1 cells, which is responsible for the phosphorylation of PKB at Ser473 and, conse-
quently, its activation. Furthermore, we observed that lithium protects against apoptosis
induced by higher albumin concentration in LLC-PK1 cells. Accordingly, it was observed that
lithium treatment reduces apoptosis in cortical tubular segments in an AKI model induced by
LPS injection [6].
A possible target downstream of mTORC2/PKB pathway activation could be GSK3β
[2,5,6]. It has been described that phosphorylation of GSK3β at Ser9 by PKB leads to its inhibi-
tion [24]. Here, we observed the modulation of the phosphorylation of GSK3β at Ser9 by lith-
ium following the same behavior as that observed on the phosphorylation of PKB at Ser473
and mTORC2 at Ser2481. These results indicate that there is a possible correlation among
mTORC2, PKB and GSK3β activities. Furthermore, Yussef et al. [39] observed that the treat-
ment of MDCK cells for 4 hours with 50 mM lithium decreases megalin expression on the
plasma membrane. It is possible to postulate that lithium treatment ameliorates PT albumin
endocytosis due to activation of the mTORC2/PKB pathway, which leads to inhibition of
GSK3β and, consequently, the increase in PT albumin endocytosis.
TII induced by albumin overload is associated with secretion of the chemokine MCP-1 by
renal cells and macrophage infiltration in the renal cortex [22,31,40,41]. We have not observed
any effect of lithium treatment on renal cortex macrophage infiltration induced by albumin
overload. Usually, macrophages under activation are driven to M1-subtype (iNOS-positive
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cell, a pro-inflammatory phenotype) or M2-subtype (arginase-1-positive cell, a resolution phe-
notype) cells [42–44]. In this context, we observed significant detection of arginase-1, suggest-
ing the possible involvement of M2-subtype macrophages rather than the M1 subtype in TII
induced by albumin overload. This idea is supported by the observation that under persistent
tissue damage, M2-subtype macrophages contribute to the development of fibrotic processes
[45]. In agreement, we observed an increase in collagen deposition during albumin overload
in PT cells. This result agrees with the previous observation that TGF-β is increased in an ani-
mal model of TII induced by albumin overload [22,46].
Lithium treatment per se induced renal injury despite the beneficial effect of attenuating
the development of TII induced by albumin overload. Interestingly, our data, together with
those previously published by other authors, indicate that lithium treatment for short periods
did not change CCr and BUN, markers of glomerular flow rate [6–8]. However, a possible
effect of lithium on the permeability of glomerular protein cannot be ruled out. Dai and
coworkers [47] showed that a single-dose lithium chloride treatment (intravenous injection of
16 mmol/kg) of BALB/c mice induced transient albuminuria correlated to podocyte foot pro-
cess effacement. Furthermore, it has been shown that chronic lithium treatment of patients
with bipolar disorders can cause glomerular diseases such as glomerulosclerosis [2]. In a recent
work, Hurcombe et al. [48] showed that GSK3 is a critical regulator of podocyte biology and,
consequently, of glomerular protein permeability. They observed that treatment of Wistar rats
with lithium for 6 months induced inhibition of GSK3 with development of proteinuria and
glomerulosclerosis. Here, we observed that lithium increases albumin uptake in LLC-PK1
cells, indicating that proteinuria and albuminuria induced by lithium treatment could not be
due to changes in protein tubular endocytosis. Thus, it is plausible to postulate that the pro-
teinuria and albuminuria observed in mice treated with lithium alone could be correlated to
an increase in glomerular protein permeability.
On the other hand, lithium decreased megalin expression and albumin endocytosis despite
increasing PKB activity in an in vivo model. These data indicate that lithium, under the condi-
tions used in the present work, has a specific tubular effect. But how does lithium induce tubular
effects? We observed that lithium increased albumin endocytosis in LLC-PK1 cells, indicating
that its inhibitory effect observed under in vivo conditions could be a consequence of changes
in cells surrounding PT cells rather than directly in PT cells. In agreement with this view, it was
observed that lithium treatment decrease M2-subtype macrophages induced by albumin over-
load (BSA+LIT group) and increased M1-subtype macrophages when the animals were treated
only with lithium (LIT group). Interestingly, in isolated human macrophages, it was observed
that lithium induces the activation of a CCL2 and tumor necrosis factor α secreting subtype
macrophage [49–51]. These results together point out a possible role of lithium in modulating
macrophage polarization, but further experiments are necessary to clarify this issue.
Evidence indicates that lithium treatment could have a beneficial outcome in AKI of vari-
ous causes [6–8]. Supporting this view, our results show that lithium decreases the develop-
ment of TII induced by albumin overload and, consequently, the progression of renal disease.
These results indicate that lithium could be used in the treatment of AKI, avoiding progression
to a chronic kidney disease (CKD). On the other hand, chronic lithium treatment has been
reported to cause kidney damage [2,4]. Thus, its use could be restricted to the treatment of
CKD rather than treatment of AKI.
Conclusion
Our results indicate that the effect of lithium treatment on renal function depends on the con-
ditions used: lithium treatment could have beneficial effects when used to treat renal disease or
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it could cause side effects on renal function when used to treat non-renal diseases. Its beneficial
effect could be correlated to a modulatory effect on the machinery involved in PT albumin
reabsorption.
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